TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kalaris Therapeutics ( (KLRS) ) just unveiled an announcement.
Kalaris Therapeutics, Inc. announced the appointment of Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025. Gall, with a robust background in financial leadership at iTeos Therapeutics and Sarepta Therapeutics, will also serve as the principal financial officer. His employment agreement includes a base salary, bonus eligibility, stock options, and severance benefits, reflecting the company’s strategic focus on strengthening its financial leadership. This appointment marks a significant shift in the company’s executive team, with Brett Hagan stepping down from his role as principal financial officer but continuing as principal accounting officer.
The most recent analyst rating on (KLRS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.
Spark’s Take on KLRS Stock
According to Spark, TipRanks’ AI Analyst, KLRS is a Underperform.
AlloVir’s stock is heavily impacted by its financial performance challenges, including consistent net losses and negative cash flow. Technical analysis also indicates a bearish trend, with prices below key moving averages and weak momentum indicators. The negative P/E ratio and absence of dividend yield further highlight valuation concerns, making it a less attractive investment at this time.
To see Spark’s full report on KLRS stock, click here.
More about Kalaris Therapeutics
Average Trading Volume: 327,679
Technical Sentiment Signal: Sell
Current Market Cap: $84.19M
For a thorough assessment of KLRS stock, go to TipRanks’ Stock Analysis page.